Richard Daniell, Executive VP, European Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), sold 124,500 shares at $16.19 ($2.0M) on 2025-03-03, disclosed to the SEC on 2025-03-05.
Scheduled sale ($2.0M) by Executive VP, European Commercial under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.19 | 49,314 | $798K | 39.9% |
| 2 | $16.19 | 49,314 | $798K | 39.9% |
| 3 | $15.56 | 12,936 | $201K | 10.1% |
| 4 | $15.56 | 12,936 | $201K | 10.1% |
| Total | $16.06 avg | 124,500 | $2.0M | 100% |
| Filing → |
| TEVA | SELL | 2026-03-06 | $6.0M | — | Filing → |
| TEVA | SELL | 2026-03-05 | $8.3M | — | Filing → |
| TEVA | SELL | 2025-12-11 | $6.6M | — | Filing → |